Guardant Health saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 89 to 92.
This proprietary rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of above 80 in the early stages of their moves.
How To Use Stock Charts To Stay Profitable And Protected
While the stock is not near an ideal buy point right now, see if it manages to form and break out of a proper base.
The company posted 0% EPS growth in its most recent report. Revenue rose 34%.
Guardant Health earns the No. 10 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and NeoGenomics are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
